Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin in Methanol Associated Optic Neuropathy
NCT02376881Phase 3Unknown
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2015
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erythropoietin in optic neuropathy, sponsored by Tehran University of Medical Sciences. Primary endpoint: Best Corrected Visual Acuity at 12 weeks. Status: unknown.
02
Drugs
erythropoietin
03
Conditions
optic neuropathy
Beyond the preview
Go deeper on NCT02376881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02376881.